

Box III Text of the abstract

Provided herein are anti-VEGF-A antibodies and anti-VEGF-A antibody conjugates thereof. In some embodiments, the anti-VEGF-A antibodies can be conjugated to a half-life extending moiety, such as a phosphorylcholine containing polymer, through a cysteine residue positioned outside the variable region of the antibodies. The anti-VEGF-A antibodies and anti-VEGF-A antibody conjugates thereof can be particularly useful for treating diabetic retinopathy. Further provided are methods for conjugating the anti-VEGF-A antibodies to the phosphorylcholine containing polymer.